Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of heart failure therapy but have a risk of hyperkalemia. Clinical guidelines recommend close monitoring of renal function and electrolyte levels throughout the course of therapy. 1 No large studies have examined whether laboratory monitoring occurs routinely in community practice.
Methods | Using the Centers for Medicare & Medicaid Services Virtual Research Data Center to access claims and summary data for beneficiaries from 10 eastern states who were alive and enrolled in fee-for-service Medicare and in the Medicare Part D prescription drug benefit for the entire 2011 calendar year, we analyzed a cohort with prevalent heart failure who newly initiated MRA therapy. We identified patients with prevalent heart failure using the Chronic Conditions Data Warehouse mid-year indicator; we identified incident MRA use by the presence of a Part D claim for eplerenone or spironolactone between May 1 and September 30, 2011, with no such claims between January 1 and April 30, 2011.
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Outcomes included measurement of serum creatinine and potassium levels before and after MRA initiation, as suggested in guidelines. We defined appropriate testing as a claim for a specific test or laboratory panel including creatinine and potassium within 120 days before initiation, 2 or more measurements during the early postinitiation period (days 1 through 10), and 3 or more measurements during the extended postinitiation period (days 11 through 90).
We counted each hospitalization as 1 test during that period. If the initial MRA prescription fill occurred within 3 days after discharge, we considered the patient to have both in-hospital initiation and 1 test during early postinitiation follow-up.
We summarized laboratory testing using frequencies with percentages. We used multivariable logistic regression to estimate associations between patient characteristics and laboratory monitoring, adjusting for demographic characteristics and comorbid conditions. We used a 2-sided P < .05 to establish statistical significance and report 95% confidence intervals. We used SAS version 9.3 (SAS Institute Inc) for all analyses. The institutional review board of the Duke University Health System approved the study and granted a waiver of consent.
Results | The study population included 10 443 Medicare beneficiaries with heart failure and incident MRA therapy. The mean (SD) age was 78.6 (7.8) years, 4142 patients (39.6%) were men, and 8354 (80%) were white. Chronic kidney disease was present in 4744 patients (45.4%), and 5571 patients (53.3%) were taking an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Combined, 756 patients (7.2%) received appropriate testing before and after MRA initiation ( Table 1) .
After initiation of MRA therapy, 1384 patients (13.3%) and 3122 patients (29.9%) received appropriate testing in early and extended follow-up, respectively. In contrast, 5782 (55.4%) and 2328 (22.3%) received no testing in early or extended followup, respectively.
Atrial fibrillation, anemia, chronic kidney disease, chronic obstructive pulmonary disease, hypothyroidism, osteoporosis, and use of diuretics were associated with a greater likelihood of appropriate laboratory testing during all periods ( Table 2) .
Discussion | Frequent laboratory monitoring of patients with heart failure following MRA initiation is supported by clinical trial evidence and endorsed in guidelines, but we observed low rates of monitoring in clinical practice. 1, 3, 4 The landmark trials of MRAs in heart failure showed MRAs significantly reduced mortality and cardiovascular readmission a Defined by the presence of at least 1 laboratory claim (or hospitalization) within 120 days before drug initiation. b Defined by the presence of 2 laboratory claims (or hospitalizations or 1 laboratory claim plus hospital discharge within 3 days before initial outpatient prescription fill) within 10 days after drug initiation. c Defined by the presence of 3 laboratory claims (or hospitalizations) within 11 to 90 days after drug initiation.
be less rigorous monitoring outside clinical trial settings, which may increase risks of adverse events associated with MRAs. 6 Closing the gap between the efficacy and effectiveness of MRAs in heart failure will require clinicians to address this issue. Quality improvement initiatives to improve appropriate laboratory monitoring are needed.
Limitations of our study include the limited population, possible inaccurate claims data, and likely unmeasured confounders. In addition, we only captured data on whether and when laboratory testing occurred but not indications for testing or uncompleted tests.
In conclusion, rates of appropriate laboratory monitoring after MRA initiation were low, and greater attention to appropriate laboratory monitoring is needed. Author Contributions: Dr Cooper had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. age (per 5 y increase above age 65 years), sex (male vs female), race (vs white race), medical history (vs absence of condition), medications (vs no use of the medication). Testing includes allowances for hospitalizations. investigated extended duration of warfarin therapy after a first episode of unprovoked pulmonary embolism. The results may be biased by the inclusion of patients with both identified and unidentified thrombophilias. Four patients with known major thrombophilia were excluded; however, screening for thrombophilia was performed in retrospect at the time of statistical analysis and included only factor V Leiden, prothrombin gene variant, elevated factor VIII, antithrombin deficiency, and anticardiolipin antibodies.
Via this screening, only 43 of 187 patients (24.7%) in the placebo group were identified to have thrombophilia compared with 597 of 1907 patients (31%) with a first episode of idiopathic venous thromboembolism in the Registro Informatizado de la Enfermedad TromboEmbolica (RIETE) who were tested for thrombophilia, further suggesting that this screening might have been insensitive. 2 Specifically, we are concerned that the placebo group was not adequately screened for antiphospholipid antibody syndrome or protein C and S deficiencies. We would expect an additional 3.6% of patients to have been identified with protein C or S deficiency had they been tested. 2 The additional yield of further lupus anticoagulant and antiphospholipid testing is uncertain as the relatively sensitive anticardiolipin testing was undertaken, but we anticipate testing for β 2 -glycoprotein I, phospholipid-dependent clotting tests, and mixing assays would identify additional thrombophilia. The British Committee for Standards in Haematology recommends screening for lupus anticoagulant as well as antibodies to β 2 -glycoprotein I after stopping anticoagulation in patients with unprovoked pulmonary embolism. 3 Furthermore, despite identifying thrombophilia, these patients were identified only in retrospect after they had been randomized to receive placebo. To determine whether the increased thromboembolism event rate in the placebo group was driven by those with thrombophilia, patients who had recurrent venous thromboembolism in the placebo group should be further scrutinized to determine if a disproportionate number had one of these identified predisposing factors.
We believe that, given the anticipated presence of thrombophilia in the placebo group of 31% and the demonstrated absolute risk reduction of 9.5 thrombotic events per person-year shown in this trial, the risk reduction may be primarily driven by inclusion of patients with thrombophilia.
We hope future studies will consider the role of thrombophilia in differentiating patients most likely to benefit from prolonged anticoagulation after pulmonary embolism.
